SCHEMBL23218702

SCHEMBL23218702

CC(C)(C)OC(=O)Cc1ccccc1OCc1cc2cc(C=O)cc(I)c2o1

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 5/20 0.37
MTNR1B P49286 5/20 0.37
L3MBTL1 Q9Y468 1/20 0.32
ALDH1A1 P00352 4/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
TBXAS1 P24557 1/20 0.31
LMNA P02545 1/20 0.31
RORC P51449 1/20 0.31
NPC1 O15118 1/20 0.30
MAPT P10636 1/20 0.30
HTT P42858 1/20 0.30
RAB9A P51151 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
CDK4 P11802 1/20 0.30
CCND1 P24385 1/20 0.30
CFD P00746 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29853074 1.00 MTNR1A (0.37) MTNR1AMTNR1BL3MBTL1ALDH1A1MEN1
SCHEMBL29853229 0.87 MTNR1A (0.37) MTNR1AMTNR1BL3MBTL1ALDH1A1MEN1
SCHEMBL23218235 0.87 MTNR1A (0.37) MTNR1AMTNR1BL3MBTL1ALDH1A1MEN1
SCHEMBL23219131 0.87 MTNR1A (0.37) MTNR1AMTNR1BL3MBTL1MEN1KMT2A
SCHEMBL29852925 0.85 TBXAS1 (0.38) MTNR1AMTNR1BL3MBTL1ALDH1A1MEN1
SCHEMBL23219011 0.85 TBXAS1 (0.38) MTNR1AMTNR1BL3MBTL1ALDH1A1MEN1
SCHEMBL23218234 0.85 MTNR1A (0.38) MTNR1AMTNR1BL3MBTL1ALDH1A1KMT2A
SCHEMBL23218513 0.85 MTNR1A (0.36) MTNR1AMTNR1BL3MBTL1ALDH1A1MEN1
SCHEMBL23218512 0.85 MTNR1A (0.36) MTNR1AMTNR1BL3MBTL1ALDH1A1LMNA
SCHEMBL29852636 0.85 MTNR1A (0.36) MTNR1AMTNR1BL3MBTL1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB MTNR1A 3930/4885MTNR1B 3580/4885L3MBTL1 4262/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB MTNR1A 3848/4885MTNR1B 2984/4885L3MBTL1 4650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.